None listed
Conditions
Brief summary
Short title EnRICH Protocol number and date X16-0447 dated 29/03/2017 This study aims to assemble a patient cohort to describe the natural history of and patterns of care for lung cancer; identify current gaps in evidence and practice for clinical quality improvement. Who is it for? You may be eligible for this study if you are aged 18 or over and have a diagnosis of lung cancer and are attending a defined clinical site for diagnosis or treatment. Study details All participants will provide demographic information, and their medical records will be used to build a profile of the participant’s cancer, including clinical and outcome information. Participants will also provide around 3 blood samples for research taken at the time of routine collection (e.g. prior to commencement of treatment, post-treatment). Biopsied tumour samples will be used to screen for biomarkers and molecular signals of disease. This research will assemble a patient cohort for identifying current gaps in evidence and practice, creating a platform for researchers across the translational research spectrum to develop and initiate studies to address these gaps.
Interventions
The aim of this program is to assemble a patient cohort to describe the natural history of and patterns of care for lung cancer. Questionnaires and blood collection will be performed once at three, six, and twelve months, and annually thereafter. The duration of the program is at least five years. Questionnaires will take approximately 10-15min to complete. Tumour tissue taken at biopsy or surgical resection will be archived for sub-studies.
Sponsors
Sydney Catalyst Translational Cancer Research Centre, University of Sydney
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients with lung cancer presenting to defined clinical sites for diagnosis or treatment, including: Patients with a new diagnosis of primary lung cancer (any histological type, any pathological/clinical stage including metastatic) undergoing primary treatment (including observation and clinical advice that no anti-cancer therapy is necessary/appropriate); curative or palliative. Patients with first progressive disease, local recurrence or new metastasis after completing previous curative treatment for non-metastatic disease at the time of initial diagnosis.
Exclusion criteria
Patients with a lung tumour which is a metastasis from a non-lung primary site. Patients diagnosed with mesothelioma. Patients with cognitive or intellectual impairment or significant mental illness who are unable to give informed consent. Patients presenting for a second specialist opinion ONLY
Outcome results
None listed